Abstracts tagged "clinical trial"

Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
John Tesser¹, Grace Wright², Vibeke Strand³, Jeffrey Kaine⁴, Karina Maslova⁵, Gregory St John⁶, Kerri Ford⁵, Amy Praestgaard⁵ and Ernest Choy⁷, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Association of Women in Rheumatology, New York, NY, ³Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁴Independent Rheumatology Consultant, Sapphire, NC, ⁵Sanofi, Cambridge, MA, ⁶Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁷CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…
Abstract Number: 1644 • ACR Convergence 2020
Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
Ali Guermazi¹, Frank Roemer², Andrew Kompel¹, Luis Diaz³, Michel Crema⁴, Mark Brown⁵, Anne Hickman⁵, Glenn Pixton⁶, Lars Viktrup⁷, Robert Fountaine⁵, Aimee Burr⁵, Sarah Sherlock⁵ and Christine West⁸, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Boston Veteran Affairs Healthcare System, Boston, MA, ⁴Boston University School of Medicine, Paris, France, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., Morrisville, NC, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tanezumab is a nerve growth factor monoclonal antibody in development for osteoarthritis (OA). Following a clinical hold due to concerns around adverse joint events,…
Abstract Number: 2026 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial
Iain McInnes¹, Jaclyn K Anderson², Marina Magrey³, Joseph Merola⁴, Yi Liu⁵, Mitsumasa Kishimoto⁶, Slawomir Jeka⁷, Cesar Pacheco Tena⁸, Xin Wang², Liang Chen², Patrick Zueger², Aileen Pangan⁹ and Frank Behrens¹⁰, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²AbbVie Inc., North Chicago, IL, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵West China Hospital of Sichuan University, Sichuan, China (People's Republic), ⁶Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁷2nd Univ Hospital, CM UMK, Bydgoszcz, Poland, ⁸Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁹Abbvie Inc., La Grange, IL, ¹⁰CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany
Background/Purpose: Upadacitinib (UPA), an oral, reversible, JAK inhibitor approved to treat rheumatoid arthritis (RA), is under evaluation for psoriatic arthritis (PsA). We assess efficacy and…
Abstract Number: 0212 • ACR Convergence 2020
Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks
Roy Fleischmann¹, In-Ho Song², Jeffrey Enejosa³, Eduardo Mysler⁴, Louis Bessette⁵, Patrick Durez⁶, Andrew Östör⁷, Jerzy Swierkot⁸, Yanna Song⁹ and Mark Genovese¹⁰, ¹Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Evanston, IL, ⁴Organización Medica de Investigación, Buenos Aires, Argentina, ⁵Laval University, Quebec, Canada, ⁶Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁷Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁸Wroclaw Medical University, Wroclaw, Poland, ⁹AbbVie Inc., North Chicago,, IL, ¹⁰Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We report safety/efficacy of upadacitinib (UPA) vs adalimumab (ADA) up to 72 weeks (wks) in patients (pts) with rheumatoid arthritis from the ongoing long-term…
Abstract Number: 0355 • ACR Convergence 2020
Collagen Turnover Markers Are Associated with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase-3 Clinical Trial
Georg Schett¹, Matthew J. Loza², Arumugam Palanichamy², Oliver FitzGerald³, Christopher Ritchlin⁴, Frédéric Baribaud⁵ and Kristen Sweet⁵, ¹Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ²Janssen Research & Development, LLC, Spring House, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS), an interleukin-23p19-subunit monoclonal antibody, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients with active…
Abstract Number: 0713 • ACR Convergence 2020
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
Daniel J Lovell¹, Hermine Brunner², Nikolay Tzaribachev³, Esi Morgan², Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Ilonka Orban¹⁵, Jason Dare¹⁶, Ivan Foeldvari¹⁷, Pierre Quartier¹⁸, Alyssa Dominique¹⁹, Tzuyung Douglas Kou¹⁹, Robert Wong¹⁹, Alberto Martini²⁰ and Nicolino Ruperto²⁰, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁶University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁷Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁸Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ¹⁹Bristol-Myers Squibb Company, Princeton, NJ, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…
Abstract Number: 0894 • ACR Convergence 2020
Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriatic Arthritis: 24-week Results from a Phase II Open Label Study
Stanley Cohen¹, Justus Fiechtner², Philip Mease³, Jeffrey Kaine⁴, Arthur Kavanaugh⁵, Yi-Lin (Irene) Cheng⁶, Claire Chou⁶, Ting-Ying Cheng⁷, Shih-Yao Lin⁶ and Mark Genovese⁸, ¹University of Texas Southwestern Medical School at Dallas, and Metroplex Clinical Research Center, Dallas, TX, ²Michigan State University, Grand Rapids,, MI, ³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁴Sarasota Arthritis Research Center, Sapphire, NC, ⁵UC San Diego Health System, San Diego, CA, ⁶AltruBio, Taipei, Taiwan (Republic of China), ⁷AltruBio, Redwood City, CA, ⁸Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Neihulizumab is a novel immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells.…
Abstract Number: 1220 • ACR Convergence 2020
Increased Serum Levels of Circulating Vimentin and Citrullinated Vimentin Are Differently Regulated by Tocilizumab and Methotrexate Monotherapies in Rheumatoid Arthritis
Patryk J. Drobinski¹, Anne C. Bay-Jensen², Anne S. Siebuhr³ and Morten A. Karsdal³, ¹University of Copenhagen/Nordic Bioscience, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Nordic Bioscience A/S, Herlev, Denmark
Background/Purpose: Presence of citrullinated protein fragments in the circulation of patients with Rheumatoid Arthritis (RA) is a highly disease-specific phenomenon. Vimentin is often a target…
Abstract Number: 1739 • ACR Convergence 2020
Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
Sofia Pazmino¹, Annelies Boonen², Diederik De Cock¹, Veerle Stouten¹, Delphine Bertrand¹, Johan Joly³, Rene Westhovens⁴ and Patrick Verschueren⁵, ¹KU Leuven, Leuven, Belgium, ²Maastricht University Medical Center, Maastricht, Netherlands, ³University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, ⁴University Hospitals Leuven, Belgium, Leuven, Belgium, ⁵University Hospital Leuven, Leuven, Belgium
Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…
Abstract Number: 2027 • ACR Convergence 2020
Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study
Philip Mease¹, Saima Chohan², Ferran J. García Fructuoso³, Alice Gottlieb⁴, Michael Luggen⁵, Proton Rahman⁶, Siba Raychaudhuri⁷, Richard Chou⁸, Alan Mendelsohn⁹, Stephen Rozzo⁹ and Ana-Maria Orbai¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Arizona Arthritis and Rheumatology Research, PLLC, Pheonix, AZ, ³Hospital CIMA Sanitas, Barcelona, Spain, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Cincinnati Rheumatic Disease Study Group, Inc, and Univ of Cincinnati College of Medicine, Cincinnati, OH, ⁶Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁷Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ⁸Division of Allergy, Immunology and Rheumatology, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, ⁹Sun Pharmaceutical Industries, Inc., Princeton, NJ, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis.1 The efficacy and safety of TIL up to…
Abstract Number: L05 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA
Benjamin Hsu¹, Jennifer Visich ², Mark Genovese ³, Kimberly Walter ², Mahru An ⁴, Remi-Martin Laberge ⁴ and Jamie Dananberg ⁴, ¹Unity Biotechnology, Brisbane, ²Unity Biotechnology, Brisbane, California, ³Stanford University, Stanford, CA, ⁴Unity Biotechnology, Brisbane, CA
Background/Purpose: A non-drug biomarker study showed senescent cell (SnC) burden in OA synovial tissue to correlate with disease severity, inflammation, and knee pain (C. Yohn,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].